<?xml version='1.0' encoding='utf-8'?>
<document id="32127372"><sentence text="Hepatic Transporter Alterations by Nuclear Receptor Agonist T0901317 in Sandwich-cultured Human Hepatocytes: Proteomic Analysis and PBPK Modeling to Evaluate Drug-Drug Interaction Risk." /><sentence text="In vitro approaches for predicting drug-drug interactions (DDIs) caused by alterations in transporter protein regulation are not well established" /><sentence text=" However, reports of transporter regulation via nuclear receptor (NR) modulation by drugs are increasing" /><sentence text=" This study examined alterations in transporter protein levels in sandwich-cultured human hepatocytes (SCHH; n = 3 donors) measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomic analysis after treatment with T0901317, the first described synthetic liver X receptor (LXR) agonist"><entity charOffset="239-247" id="DDI-PubMed.32127372.s4.e0" text="T0901317" /></sentence><sentence text=" T0901317 treatment (10 Î¼M, 48 h) decreased the levels of organic cation transporter (OCT) 1 (0" /><sentence text="22-, 0" /><sentence text="43- and 0" /><sentence text="71-fold of control) and organic anion transporter (OAT) 2 (0" /><sentence text="38-, 0" /><sentence text="38- and 0" /><sentence text="53-fold of control), and increased multidrug resistance protein (MDR) 1 (1" /><sentence text="37-, 1" /><sentence text="48 and 1" /><sentence text="59-fold of control)" /><sentence text=" The induction of NR downstream gene expression support the hypothesis that T0901317 off-target effects on farnesoid X receptor (FXR) and pregnane X receptor (PXR) activation are responsible for the unexpected changes in OCT1, OAT2 and MDR1" /><sentence text=" Uptake of the OCT1 substrate metformin in SCHH was decreased by T0901317 treatment"><entity charOffset="30-39" id="DDI-PubMed.32127372.s16.e0" text="metformin" /><entity charOffset="43-47" id="DDI-PubMed.32127372.s16.e1" text="SCHH" /><pair ddi="false" e1="DDI-PubMed.32127372.s16.e0" e2="DDI-PubMed.32127372.s16.e0" /><pair ddi="false" e1="DDI-PubMed.32127372.s16.e0" e2="DDI-PubMed.32127372.s16.e1" /></sentence><sentence text=" Effects of decreased OCT1 levels on metformin were simulated using a physiologically-based pharmacokinetic (PBPK) model"><entity charOffset="37-46" id="DDI-PubMed.32127372.s17.e0" text="metformin" /></sentence><sentence text=" Simulations showed a clear decrease in metformin hepatic exposure resulting in a decreased pharmacodynamic effect"><entity charOffset="40-49" id="DDI-PubMed.32127372.s18.e0" text="metformin" /></sentence><sentence text=" This DDI would not be predicted by the modest changes in simulated metformin plasma concentrations"><entity charOffset="68-77" id="DDI-PubMed.32127372.s19.e0" text="metformin" /></sentence><sentence text=" Altogether, the current study demonstrated that an approach combining SCHH, proteomic analysis, and PBPK modeling is useful for revealing tissue concentration-based DDIs due to unexpected regulation of hepatic transporters by NR modulators"><entity charOffset="71-75" id="DDI-PubMed.32127372.s20.e0" text="SCHH" /><entity charOffset="227-229" id="DDI-PubMed.32127372.s20.e1" text="NR" /><pair ddi="false" e1="DDI-PubMed.32127372.s20.e0" e2="DDI-PubMed.32127372.s20.e0" /><pair ddi="false" e1="DDI-PubMed.32127372.s20.e0" e2="DDI-PubMed.32127372.s20.e1" /></sentence><sentence text=" SIGNIFICANCE STATEMENT: This study utilized an approach combining sandwich-cultured human hepatocytes, proteomic analysis, and physiologically-based pharmacokinetic modeling to evaluate alterations in pharmacokinetics (PK) and pharmacodynamics (PD) due to transporter regulation by nuclear receptor modulators" /><sentence text=" The importance of this approach from a mechanistic and clinically-relevant perspective is that it can reveal drug-drug interactions (DDIs) due to unexpected regulation of hepatic transporters, and enable prediction of altered PK and PD changes, especially for tissue concentration-based DDIs" /><sentence text="" /></document>